Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,179 recruiting studies in this area right now.
By phase
- Not applicable2,932
- Phase 2754
- Phase 1537
- Phase 3384
- Phase 1/Phase 2297
- Phase 4212
- Phase 2/Phase 363
Top conditions
- Breast Cancer1,225
- Melanoma183
- Rheumatoid Arthritis141
- Metastatic Breast Cancer139
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer91
- Ovarian Cancer90
- Psoriasis88
- Breast Carcinoma82
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)66
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University65
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals47
- Assistance Publique - Hôpitaux de Paris41
- Mayo Clinic41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California422
- Arizona157
- Florida131
- Alabama126
- New York109
- Texas107
- Massachusetts93
- Maryland91
- Pennsylvania75
- North Carolina68
Recruiting studies5,179 total
- NCT05858606Recruiting
Study genes and causes of very short height in children
This study looks at your child’s growth history and performs genetic testing to better understand why some children are very short. It may help researchers identify possible underlying causes and improve care, using blood samples from the child and both parents.
MontpellierAges 4–18 - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05862272RecruitingPhase 3
Testing long-term bone density support in fibroids or endometriosis
This study tests how well a long-term treatment using a relugolix combination tablet helps protect bone density in women who have uterine fibroids or endometriosis. It may help people who are at risk of bone thinning while receiving hormone-related symptom treatment.
Mobile, AlabamaAges 18–50 - NCT05865054Recruiting
MRI check in early suspected giant cell arteritis
This trial tests how well a special MRI (picture scan) can evaluate giant cell arteritis when it’s newly suspected and symptoms started recently. It may help doctors confirm the diagnosis and decide on treatment sooner by comparing MRI findings with standard testing like biopsy or ultrasound.
Rochester, MinnesotaAges 50 years+ - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT05866432RecruitingPhase 2
Dato-DXd for triple-negative breast cancer brain metastases
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Vienna, State of ViennaAges 18–100 - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT05867966Recruiting
Testing a hypnosis-based program for symptom clusters in cancer
This trial studies whether a hypnosis-based approach can help reduce a selected set of troubling symptoms in people who have finished treatment for certain early-stage (non-metastatic) cancers. It aims to understand which symptom patterns improve and how well the intervention works.
LiègeAges 18 years+ - NCT05868707RecruitingPhase 3
Tested OH2 injection for melanoma after standard treatments fail
This Phase 3 study tests OH2 injection in people with stage III or IV melanoma that has come back or spread after at least two prior treatment types. If you qualify, you may receive OH2 injection to help shrink tumors or slow disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05871216Recruiting
Study of joint instability in people with loose joints
This trial is testing how to assess and manage joint instability in people who have unusually loose (hypermobile) joints. If you have moderate to severe loose joints, you may be able to join after screening checks like movement tests and health history.
BolognaAges 18–60 - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05874492Recruiting
Spa therapy for radiation-related skin fibrosis after cancer
This trial tests whether a spa therapy program can improve “fibrosis,” or stiffened/scarred tissue and related skin problems, after radiotherapy for breast cancer or upper head/neck cancers. It aims to see if treatment can improve quality of life for people who still have moderate-to-worse symptoms months after radiation.
BordeauxAges 18 years+ - NCT05876416Recruiting
Study genetics of rare bone growth disorders
This study looks at genetic causes of skeletal (bone growth) disorders in people who show signs based on height and bone imaging. Genetic testing may help explain what’s behind the condition, especially when it seems inherited.
StockholmAges Any age - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT05877859Recruiting
Testing pembrolizumab with chemo before breast cancer surgery
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
Atlanta, GeorgiaAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT05878964Recruiting
Study of skin health and quality of life during cancer treatment
This trial looks at how cancer treatments (anti–PD-1/PD-L1/CTLA-4 medicines or CDK inhibitors) affect your skin and overall quality of life. You may fill out questionnaires during the study to help researchers understand changes over time.
RomaAges 18 years+ - NCT05878977Recruiting
Testing biomarkers in immunotherapy for advanced melanoma
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
LjubljanaAges 18 years+ - NCT05883371Recruiting
IMPACT autoimmune study registry for people on biologic medicines
This study is a registry that collects health information from adults with certain autoimmune conditions who are currently using (or have been recommended) biologic or DMARD medicines. It may help researchers better understand these diseases and how treatments affect people over time.
Columbus, OhioAges 18–70 - NCT05887102Recruiting
Program to help women take hormone pills after breast cancer
This study tests a pharmacy-based program (called PACHA) designed to help women remember and stick with hormone (endocrine) treatment after breast cancer. It may help by improving support and follow-through during the first months after starting the pills.
Québec, QuebecAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,179 recruiting dermatology studies from the U.S. registry right now, out of 8,312 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.